09:11 AM EST - Oncolytics Biotech Inc : Today announced the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate therapy. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.42.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACC&qmodStoryID=7342688485691240
